1. The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
   Yuji Oe et al, 2022, Kidney and Dialysis CrossRef
2. SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice
   Rebeca Ortega et al, 2019, Arteriosclerosis, Thrombosis, and Vascular Biology CrossRef
3. SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules
   Yajiao Wang et al, 2023, Frontiers in Nephrology CrossRef
4. Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
   Jing Xu et al, 2021, Cells CrossRef
5. Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease
   Hongru Yan et al, 2021, Diabetic Nephropathy CrossRef
6. Role of Dendritic Cell in Diabetic Nephropathy
   Hyunwoo Kim et al, 2021, International Journal of Molecular Sciences CrossRef
7. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives
   Yu Wang et al, 2023, Frontiers in Endocrinology CrossRef
8. High mobility group box 1 and homocysteine as preprocedural predictors for contrast-induced acute kidney injury after percutaneous coronary artery intervention
   Changhua Mo et al, 2022, International Urology and Nephrology CrossRef
9. Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy
   Na Li et al, 2022, Current Pharmaceutical Design CrossRef
10. Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction
    Ami Sotokawauchi et al, 2020, International Journal of Molecular Sciences CrossRef
11. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
    Patrick C. Baer et al, 2020, International Journal of Molecular Sciences CrossRef
12. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective
    Danúbia Silva dos Santos et al, 2020, American Journal of Physiology-Cell Physiology CrossRef
13. Multiplex Bead Array Assay of a Panel of Circulating Cytokines and Growth Factors in Patients with Albuminuric and Non-Albuminuric Diabetic Kidney Disease
    Vadim V. Klimontov et al, 2020, Journal of Clinical Medicine CrossRef
14. Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
    Qingchun Zeng et al, 2021, Frontiers in Cardiovascular Medicine CrossRef
15. Toll-like receptors 2 and 4 stress signaling and sodium-glucose cotransporter-2 in kidney disease
    Vishwadeep Shelke et al, 2023, Molecular and Cellular Biochemistry CrossRef
16. DF-5 COMPOUND DELAYS DEVELOPMENT OF DIABETIC NEPHROPATHY IN RATS
    A. A. Spasov et al, 2023, Pharmacy & Pharmacology CrossRef
17. Effect of Empagliflozin on Candida glabrata Adhesion to Vaginal Epithelial Cells
    Naomi Sugimoto et al, 2022, Medical Mycology Journal CrossRef
18. SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
    Qing Zhang et al, 2024, Frontiers in Cardiovascular Medicine CrossRef
19. Ferroptosis: a new strategy for Chinese herbal medicine treatment of diabetic nephropathy
    Maoying Wei et al, 2023, Frontiers in Endocrinology CrossRef
20. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review
    Jinfang Song et al, 2023, Kidney and Blood Pressure Research CrossRef
21. A Novel Role of Dapagliflozin in Mitigation of Acetic Acid-Induced Ulcerative Colitis by Modulation of Monocyte Chemoattractant Protein 1 (MCP-1)/Nuclear Factor-Kappa B (NF-κB)/Interleukin-18 (IL-18)
    Mohamed Kh. ElMahdy et al, 2021, Biomedicines CrossRef